What Role Do Fluoroquinolone Antimicrobial Agents Play in Cardiac Dysfunction and Altered Glycemic Control?

Journal of Pharmacy Practice

Volumn 16, Issue 5, 2003, Pages 349-360

  Smith, Karen M ^b   Lomaestro, Ben M ^a  

^a ALBANY MEDICAL CENTER   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Fluoroquinolone; Hyperglycemia; Hypoglycemia; Torsades

Indexed keywords

AMITRIPTYLINE; ASTEMIZOLE; AZITHROMYCIN; BUTYROPHENONE; CHLORPROMAZINE; CLARITHROMYCIN; DESIPRAMINE; DISOPYRAMIDE; DOXEPIN; ERYTHROMYCIN; FLUPHENAZINE; HALOPERIDOL; IMIPRAMINE; MESORIDAZINE; NORTRIPTYLINE; PENTAMIDINE; PHENOTHIAZINE; PIMOZIDE; PROCAINAMIDE; PROCHLORPERAZINE; QUETIAPINE; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RISPERIDONE; SPARFLOXACIN; TELITHROMYCIN; TERFENADINE; THIORIDAZINE; UNINDEXED DRUG; ZIPRASIDONE;

AGE DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ELECTROLYTE BALANCE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEART ARRHYTHMIA; HEART DISEASE; HEART FUNCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; QT INTERVAL; QT PROLONGATION; REVIEW; RISK FACTOR; SIDE EFFECT; TORSADE DES POINTES;

EID: 0344862014     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/0897190003257626     Document Type: Review

References (42)

1. Paladino JA. Is more than one quinolone needed in clinical practice? Ann Pharmacother. 2001;35:1085-1095.
2. Breen J, Skuba K, Grasela D. Safety and tolerability of gatifloxacin, an advanced-generation 8-methoxy fluoroquinolone. J Resp Dis. 1999;20:S70-S76.
3. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis. 1999;28:352-364.
4. Owens RC. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy. 2001;21(3):301-319.
5. Ball P. Quinolone-inducted QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother. 2000;45:557-559.
6. Shah RR. The significance of QT interval in drug development. J Clin Pharmacol. 2002;54:188-202.
7. Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother. 2002;49:593-596.
8. Committee for Proprietary Medicinal Products. Points to Consider: The Assessment of the Potential for QTc Interval Prolongation by Non-Cardiovascular Medicinal Products. London: The European Agency for Evaluation of Medicinal Product; 1997.
9. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy. 2001;21(10S):253S-272S.
10. Heinemann SH. Pharmacology review: effects of fluoroquinolones on HERG channels, stably expressed in HEK293 cells (Bayer report no. R 7854; study no. 72064976). Available at: http://www.fda.gov/cder/foi/nda/2001/21277_Avelox_pharmr.pdf. Accessed February 28, 2003.
11. Anderson ME, Mazur A, Yang T, et al. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther. 2001;296:806-810.
12. + channel HERG. Mol Pharmacol. 2001;59:122-126.
13. Avelox [package insert]. West Haven, Conn: Bayer Corporation; 2002.
14. Noel GJ, Abels R, Minton N, et al. Effect of three fluoroquinolones (FQs) on QTc intervals in healthy volunteers [abstract]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 2001:24.
15. Tequin [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2002.
16. Bertino JS, Owens RC, Carnes TD, et al. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis. 2002;34:861-863.
17. Iannini PB, Circiumaru I. Gatifloxacin-induced QTc prolongation and ventricular tachycardia. Pharmacotherapy. 2001;21:361-362.
18. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy. 2001;21(12):1468-1472.
19. Iannini PB, Circiumaru J, Byazrova E, et al. QTc prolongation associated with levofloxacin. Br Med J. 2001;7277:46-47.
20. Cipro [package insert]. West Haven, Conn: Bayer Corporation; 2002.
21. Owens RC, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy. 2002;22(5):663-672.
22. Schaffer D, Singer S, Korvick J. Macrolide and fluoroquinolone associated torsades de pointes: a review of the FDA adverse event reported system [abstract]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 2001:20.
23. Levaquin [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc; 2002.
24. Floxin [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc; 1998.
25. Noroxin [package insert]. West Point, Pa: Merck & Company, Inc; 1999.
26. Menzies DJ, Dorsainvil PA, Dunha BA, et al. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med. 2002;113:232-234.
27. Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Hardman JG, Limbird LE, Molinoff PB, et al, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996:1487-1517.
28. Maeda N, Tamagawa T, Niki I, et al. Increase in insulin release from rat pancreas islets by quinolone antibiotics. Br J Pharmacol. 1996;117(2):372-376.
29. Lefébvre PJ, Scheen AJ, Hypoglycemia. In: Porte D, Sherwin RS, eds. Ellenberg & Rifkin's Diabetes Mellitus. 5th ed. Stamford, Conn: Appleton & Lange; 1997:1307-1328.
30. Fraser AG, Harrower AD. Convulsions and hyperglycaemia associated with nalidixic acid. Br Med J. 1977;2(6101):1518.
31. Jick SS, Jick H, Dean AD. A follow-up safety study of ciprofloxacin users. Pharmacotherapy. 1993;13(5):461-464.
32. Roberge RJ, Kaplan R, Frank R, et al. Glyburide-ciprofloxacin interaction with resistant hypoglycemia. Ann Emerg Med. 2000;36:160-163.
33. Whitely M, Worlding J, Patel S, et al. Hypoglycemia in a diabetic patient, associate with ciprofloxacin therapy [case report]. Pract Diabetes. 1993;10:35.
34. US Food and Drug Administration, Center for Drug Evaluation and Research. New drug approval packages-Levaquin/ Levofloxacin (R. W. Johnson Pharmaceuticals application no 020634, parts 1, 2, 3, & 4). Available at: http://www.fda/gov/cder/foi/nda/index96.htm. Accessed March 1, 2003.
35. Parilo MA. Gatifloxacin-associated hypoglycemia. J Pharm Technol. 2002;18:319-320.
36. US Food and Drug Administration, Center for Drug Evaluation and Research. Data taken for review of the safety of moxifloxacin hydrochloride from the original NDA as found in parts 4 and 5. Available at: http://www.fda.gov/cder/nda/99/21_085_Avelox_ medr_P1. Accessed October 27, 2002.
37. Grasela DM. Clinical pharmacology of gatifloxacin, a new fluoroquinolone. Clin Infect Dis. 2000;31(suppl):S51-S58.
38. Gajjar DA, LaCreta FP, Uderman HD, et al. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy. 2000;20(suppl):49S-58S.
39. Gajjar DA, LaCreta FP, Kollia GD, et al. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with non-insulin dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy. 2000;20(suppl):76S-86S.
40. Grasela DM, LaCreta FP, Kollia GD, et al. Lack of effect of multiple-dose gatifloxacin (GAT) on oral glucose tolerance (OGTT), glucose and insulin homeostasis, and glyburide pharmacokinetics (PK) in type II non-insulin dependent diabetes mellitus (NIDDM) [abstract]. In: Proceedings and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1999:11.
41. Baker SE, Hang Hangi MC. Possible gatifloxacin-induced hypoglycemia. Ann Pharmacother. 2002;36:1722-1726.
42. Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther. 2003;73:292-303.